Amicus Therapeutics Inc. (FOLD)

9.74
0.02 0.20
NASDAQ : Health Technology
Prev Close 9.76
Open 9.74
Day Low/High 9.62 / 9.90
52 Wk Low/High 7.11 / 14.62
Volume 1.01M
Avg Volume 3.52M
Exchange NASDAQ
Shares Outstanding 254.81M
Market Cap 2.58B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

I'm Unapologetically Overweight in These 2 Sectors

I'm Unapologetically Overweight in These 2 Sectors

The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.

A Pair of Rare Disease Biotech Concerns Worth a Good Look

A Pair of Rare Disease Biotech Concerns Worth a Good Look

Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

2 Small Biotechs With Sagging Shares but Promising Prospects

2 Small Biotechs With Sagging Shares but Promising Prospects

The stocks of these two developmental concerns have slid recently, but there are reasons to believe they will improve.

Amicus Therapeutics Looks Impressive If it Can Rally Above $18

Amicus Therapeutics Looks Impressive If it Can Rally Above $18

The combination of three charts gives me a bullish view on FOLD.

2 Small-Cap Stocks That Are Still a Bargain

2 Small-Cap Stocks That Are Still a Bargain

Despite the January rally, this biotech name and building materials firm still have further to rise.

Three to Watch in Biotech

Other than the Dow, most of major market indices are showing small gains heading into the last hour of trading. The biotech sector has not participated in today's rally and is down some 0.75% on the day so far. I am watching a few small biotech and ...

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Markets Struggle to Find Direction

Markets continue to meander between being slightly up or slightly down as equities struggle for a direction after yesterday's big slide. New homes sales for the month of February were above expectations with the average selling price 10% above the s...

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Markets Seeing A Narrow Trading Range

Markets have weakened over the past hour. There has been a very narrow trading range so far today. Biotech continued to strengthen. I think the sector is gaining a bit of strength as some small caps like Amicus Therapeutics  present at the JP Morgan...

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Biotech Stocks to Watch: Part 1

Biotech Stocks to Watch: Part 1

Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.

Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers

Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers

The pharmaceutical company on Oct. 3 said the FDA has approved its generic version of Teva's multiple sclerosis drug Copaxone.

Remember, Fed News Is a Trigger for the Computers

Remember, Fed News Is a Trigger for the Computers

So I'm staying focused on stock picking.

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

It's hard to predict when momentum will slow, but it could be time to take some profits when the market is as strong as this morning.

The Flippers Are at Work and the Bears Are Hopeful

The Flippers Are at Work and the Bears Are Hopeful

Apple and its suppliers are dragging the market down.

Time to Bring Amicus Therapeutics Into the 'FOLD'

Time to Bring Amicus Therapeutics Into the 'FOLD'

Shares of this biotech look ready for further strong gains.

REITs Are Strong on M&A News

The market is maintaining slight gains across the board as we approach the noon hour. Lodging REITS are strong today on the back of the news that RLJ Lodging Trust  has received a competing buyout offer from a PE firm for $24 a share. Shares are up ...

Trump's FDA: A Friendlier Biotech Sheriff

Trump's FDA: A Friendlier Biotech Sheriff

There still will be winners and losers, but the new administration's FDA is a net plus for the industry.

Keep Biotech Trigger Fingers Holstered

Keep Biotech Trigger Fingers Holstered

Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.

Vegas Baby: Rolling '777s' in Biotech

Vegas Baby: Rolling '777s' in Biotech

Three small-cap biotechs with attractive risk/reward profiles.

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

3 Small Biotechs With Insider Buying

3 Small Biotechs With Insider Buying

Insiders have an edge in this complex sector, so it's worth checking them out.

A Biotech Trio to Like Going Into 2017

A Biotech Trio to Like Going Into 2017

Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.

4 Promising Small Biotechs to Watch in 2017

4 Promising Small Biotechs to Watch in 2017

Veterinary drug play Aratana Therapeutics is among the potential solid performers next year.